Acquired by Merck or Not, Seagen Will, Sooner or Later, Outperform

Is Merck to Acquire Seagen?
The Wall Street Journal reported that Merck is in advanced talks to buy Seagen in a deal that could be worth $40 billion or more. The report, cited by people familiar with the matter, said that the companies are discussing a price above $200 a share for SGEN.

It is said that the acquisition will help Merck boost its products portfolio before its cancer drug Keytruda loses its marketing exclusivity in 2028. The companies may be looking forward to sealing the deal on or before the announcement of Merck's second-quarter earnings, which are . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.